首页> 美国卫生研究院文献>Indian Journal of Clinical Biochemistry >Serum Testosterone 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders
【2h】

Serum Testosterone 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders

机译:前列腺疾病患者的血清睾丸激素17β-雌二醇和PSA水平

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prostate carcinoma is the most frequently diagnosed malignancy and the second leading cause of death as a result of cancer in men in the US and other parts of the world. There are conflicting reports on the serum levels of testosterone and 17β-estradiol (E2) in benign prostatic hyperplasia (BPH) and prostate cancer. This study was designed to evaluate the serum concentrations of these hormones in patients with these disorders. Serum levels of prostate specific antigen (PSA), total testosterone and estradiol were determined in 228 subjects comprising of 116 subjects with BPH, 62 subjects with prostate cancer (CaP) and 50 age-matched apparently healthy controls, using ELISA methods. PSA levels were significantly elevated (p < 0.05) in BPH subjects than controls, while there was no significant difference (p > 0.05) in testosterone and estradiol levels of these subjects. PSA and estradiol levels were significantly higher (p < 0.05) in CaP subjects than in controls, while there was no observed significant difference (p > 0.05) in testosterone levels. CaP subjects had significantly raised PSA, testosterone, and estradiol levels than BPH subjects. The mean molar ratio of testosterone: E2 was lowest among CaP patients (134:1) and highest among controls (166:1). Significant positive correlation between PSA and 17β-estradiol was observed in prostate disorders (BPH and CaP patients: r = 0.347; p = 0.000). Significant negative correlations between testosterone and PSA were also observed among BPH patients (r = −0.221, p = 0.049) and control subjects (r = −0.490, p = 0.000). No significant correlation existed between testosterone and PSA in CaP patients (r = 0.051, p = 0.693). Correlations between age and estradiol in both BPH and CaP were not significant (p > 0.05). This study has shown that, there was a significant increase in serum estradiol in CaP subjects, while the testosterone levels in both BPH and CaP subjects were not different from those of controls.
机译:在美国和世界其他地区,前列腺癌是最常被诊断出的恶性肿瘤,并且是导致癌症死亡的第二大主要原因。关于良性前列腺增生(BPH)和前列腺癌中睾丸激素和17β-雌二醇(E2)的血清水平存在矛盾的报道。这项研究旨在评估患有这些疾病的患者中这些激素的血清浓度。使用ELISA方法,在228名受试者中确定了血清的前列腺特异性抗原(PSA),总睾丸激素和雌二醇的水平,其中包括116名BPH受试者,62名前列腺癌(CaP)和50名年龄相匹配的明显健康对照。 BPH受试者的PSA水平显着高于对照组(p <0.05),而这些受试者的睾丸激素和雌二醇水平无显着差异(p> 0.05)。 CaP受试者的PSA和雌二醇水平显着高于对照组(p <0.05),而睾丸激素水平没有观察到显着差异(p> 0.05)。与BPH受试者相比,CaP受试者的PSA,睾丸激素和雌二醇水平显着升高。在CaP患者中,睾丸激素:E2的平均摩尔比最低(134:1),而在对照组中最高(166:1)。在前列腺疾病(BPH和CaP患者:r = 0.347; p = 0.000)中观察到PSA与17β-雌二醇之间存在显着正相关。在BPH患者(r = −0.221,p = 0.049)和对照受试者(r = −0.490,p = 0.000)之间也观察到睾丸激素和PSA之间的显着负相关。 CaP患者的睾丸激素和PSA之间无显着相关性(r = 0.051,p = 0.693)。 BPH和CaP中年龄与雌二醇之间的相关性不显着(p> 0.05)。这项研究表明,CaP受试者的血清雌二醇显着增加,而BPH和CaP受试者的睾丸激素水平与对照组无差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号